N Neurocrine Biosciences, Inc.
| Market Cap | $13.21B |
| P/E Ratio | 28.18 |
| Forward P/E | 13.54 |
| Dividend Yield | — |
| Beta | 0.35 |
| 52W Range | $87.54 - $155.63 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Dodge & Cox Dodge & Cox | 0.42% | $781.21M | 5,508,042 | Reduce 0.87% |
Insider Trading
| Insider Name of the company insider who made the trade 13 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Gano KyleChief Executive Officer | Sale | 1,812 | $132.71 | $240.48K | 16 Jan 2026 | 20 Jan 2026 |
| Gano KyleChief Executive Officer | Sale | 34,588 | $132.70 | $4.59M | 16 Jan 2026 | 20 Jan 2026 |
| Norwalk Leslie V | Sale | 1,190 | $155.09 | $184.56K | 16 Dec 2025 | 17 Dec 2025 |
| Norwalk Leslie V | Sale | 5,000 | $152.23 | $761.14K | 15 Dec 2025 | 17 Dec 2025 |
| Lippoldt DarinChief Legal Officer | Sale | 4,376 | $159.65 | $698.62K | 08 Dec 2025 | 10 Dec 2025 |
| LYONS GARY ADirector | Sale | 15,000 | $152.61 | $2.29M | 03 Dec 2025 | 04 Dec 2025 |
| BENEVICH ERICChief Commercial Officer | Sale | 5,970 | $151.74 | $905.88K | 28 Nov 2025 | 02 Dec 2025 |
| Eric BenevichChief Commercial Officer | Sale | 5,970 | $151.74 | $905.88K | 28 Nov 2025 | 02 Dec 2025 |
| MORROW GEORGE J | Sale | 15,000 | $143.37 | $2.15M | 25 Nov 2025 | 26 Nov 2025 |
| RASTETTER WILLIAM H | Sale | 18,000 | $151.82 | $2.73M | 05 Nov 2025 | 06 Nov 2025 |
| William H RastetterDirector | Sale | 18,000 | $151.82 | $2.73M | 05 Nov 2025 | 06 Nov 2025 |
| Gano KyleChief Executive Officer | Sale | 300 | $141.97 | $42.59K | 04 Nov 2025 | 04 Nov 2025 |
| Kyle GanoChief Executive Officer | Sale | 300 | $141.97 | $42.59K | 04 Nov 2025 | 04 Nov 2025 |
Frequently Asked Questions
What is NBIX stock price today?
Neurocrine Biosciences, Inc. (NBIX) is currently trading at $131.60. The stock has a 52-week range of $87.54 to $155.63 and a market capitalization of $13.21B.
Is NBIX a good stock to buy in 2026?
Neurocrine Biosciences, Inc. has a P/E ratio of 28.2 (forward P/E: 13.5), a dividend yield of none, and 1-year performance of +27.9%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling NBIX stock?
There have been 13 insider transactions for NBIX in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has NBIX stock performed over the past year?
Neurocrine Biosciences, Inc. (NBIX) has returned +27.9% over the past 12 months. The stock traded between $87.54 and $155.63 during this period, and is currently at $131.60.
Which hedge funds own NBIX (Neurocrine Biosciences, Inc.)?
1 tracked hedge funds currently hold NBIX in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is NBIX's market cap and valuation?
Neurocrine Biosciences, Inc. (NBIX) has a market capitalization of $13.21B. The trailing P/E ratio is 28.2 and forward P/E is 13.5. The stock is classified in the Healthcare sector.
What is NBIX's revenue and profitability?
Neurocrine Biosciences, Inc. reported revenue of $2.86B with net income of $478.60M and a profit margin of 0.17%. The stock has a beta of 0.35.
What sector is NBIX in and who are its biggest institutional holders?
Neurocrine Biosciences, Inc. (NBIX) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.